Core Viewpoint - The announcement by Lai Kai Pharmaceutical-B (02105) regarding the licensing agreement for its breast cancer candidate drug LAE002 (afuresertib) to Qilu Pharmaceutical is a significant development in the domestic biopharmaceutical sector, with a total agreement value of up to 2.045 billion yuan [1] Group 1: Company Developments - Lai Kai Pharmaceutical's stock rose over 6%, currently trading at 17.27 HKD with a transaction volume of 32.1493 million HKD [1] - The licensing agreement includes an upfront payment and a revenue-sharing model where Lai Kai will receive 10%-20% of sales, ensuring funding for further research and development [1] Group 2: Product and Market Potential - LAE002 is a potent AKT inhibitor, with its global development progress second only to AstraZeneca's Capivasertib in the HR+/HER2- breast cancer indication [1] - The peak sales potential for LAE002 in the Chinese market is estimated to reach 2 billion yuan, while global sales could reference Capivasertib, which is projected to achieve 700-800 million USD in sales this year, with peak sales potentially exceeding 1-2 billion USD [1]
来凯医药-B涨超6% 业内预计LAE002在中国市场销售峰值有望达到20亿元